Crossmark

Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study

Crossref DOI link: https://doi.org/10.1186/s12944-020-01295-7

Published Online: 2020-05-30

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dunbar, Richard L. https://orcid.org/0000-0002-7059-4794
Gaudet, Daniel

Davidson, Michael

Rensfeldt, Martin

Yang, Hong

Nilsson, Catarina

Kvarnström, Mats

Oscarsson, Jan
License Information

Text and Data Mining valid from 2020-05-30

Version of Record valid from 2020-05-30
More Information

Article History

Received: 23 May 2019

Accepted: 21 May 2020

First Online: 30 May 2020

Ethics approval and consent to participate

: The clinical study protocol was reviewed and approved by the institutional review board or independent ethics committee for each of six study centers in the USA and Canada. The study was conducted in compliance with the ethical principles in the Declaration of Helsinki and applicable amendments, and the International Conference on Harmonisation Good Clinical Practice Guidelines. All participants provided written, informed consent.

: Not applicable.

: MD was the Founder and Chief Medical Officer of Omthera (manufacturer of Epanova), prior to its acquisition by AstraZeneca. RLD was employed by ICON Clinical Services during the bulk of the manuscript preparation, and is currently an employee and stock shareholder of Amarin Pharma, Inc. RLD has received grant support from Omthera and AstraZeneca. DG has received grant support from AstraZeneca and GlaxoSmithKline. JO and CN are employees of AstraZeneca. MK and HY were employees of AstraZeneca when the study was conducted.

Document is current

Any future updates will be listed below